Tritherapy, associating nucleozide reverse-transcriptase (RT) inhibitors with either non-nucleoside RT inhibitors or with protease inhibitors was introduced in 1996 and spectacularly impacted the outcome of infection: it completely suppressed viral replication and boosted the CD4+ T-cell counts [142]. This evidence concerns the gene CD4 and infection.